Clinical Trial Services Market Size, Growth, Share & Trends Analysis
Report Code
PH 1622
Published in
Mar, 2025, By MarketsandMarkets™
Clinical Trial Services Market by Type (Laboratory, Monitoring, Recruitment, PV, Data Management), Phase (I, II, III), Therapy (Oncology, Neurology, Dermatology, CVD), Modality (Biologics, Devices), Delivery Model (FSP, Hybrid) - Global Forecast to 2030
USD 101.85 BN
MARKET SIZE, 2030
CAGR 8.9%
(2025-2030)
522
REPORT PAGES
661
MARKET TABLES
OVERVIEW
Source: Secondary Research, Interviews with Experts, MarketsandMarkets Analysis
The global clinical trial services market is expected to reach USD 101.86 billion in 2030 from USD 66.59 billion in 2025 at a CAGR of 8.9% during the forecast period. Factors such as the growing focus on patient-centric clinical trials such as Decentralized Clinical trials (DCTs) and the increasing number of clinical trials for precision/personalized medicines are supporting the growth of this market.
KEY TAKEAWAYS
-
By RegionThe North American market accounted for a 45.0% revenue share in 2024. Large share is attributed to the presence of a well-established pharmaceutical industry, the rising number of ongoing clinical trial studies, growing R&D expenditure, and a strong presence of CROs.
-
By ServicesBy services, the patient recruitment & retention segment is expected to register the highest CAGR of 10.7%.
-
By PhaseBy phase, the phase III segment is projected to grow at the fastest rate from 2025 to 2030.
-
By End userBy end user, the Pharmaceutical & Biotpharmaceutical Companies segment accounted for a 70.9% revenue share in 2024. Market growth is driven by the increased investments in drug research and development, expanding R&D pipelines, rising expenditure on novel therapies, and the growing trend of outsourcing clinical and laboratory testing services.
The global clinical trial services market is driven by the increasing adoption of patient-focused approaches, such as decentralized clinical studies (DCTs), and the rising demand for personalized medicine, supported by higher R&D investments.
TRENDS & DISRUPTIONS IMPACTING CUSTOMERS' CUSTOMERS
The impact on business in the clinical trial services market across phases I to IV is shaped by evolving sponsor requirements, technological innovations, and increasing trial complexity. Pharmaceutical, biotechnology, medical device firms, and CROs are primary clients of clinical trial services, relying on specialized providers for crucial functions like trial management, patient recruitment, site monitoring, data analytics, and regulatory compliance. Demand is driven by the rise in advanced and personalized therapies, the globalization of clinical research, and a growing emphasis on patient-centric, decentralized and hybrid clinical trial models.
Source: Secondary Research, Interviews with Experts, MarketsandMarkets Analysis
MARKET DYNAMICS
Drivers
Impact
Level
Level
-
Rising R&D investments and patent cliff pressure to support market growth
-
Increasing focus on patient-centric trials (DCT)
RESTRAINTS
Impact
Level
Level
-
No restraints
OPPORTUNITIES
Impact
Level
Level
-
Regulatory requirement for increasing diversity in clinical trials
-
Growing role of real-world evidence in drug approvals
CHALLENGES
Impact
Level
Level
-
Cybersecurity or intellectual property concerns
-
Challenge of patient retention
Source: Secondary Research, Interviews with Experts, MarketsandMarkets Analysis
Driver: Advancement in Imaging Technology
Major pharmaceutical companies are facing a near patent cliff leading to stiff competition from biosimilars and generics, pressuring these companies to invest substantially towards R&D and increasing the demand for outsourced clinical trial services. According to IQVIA’s R&D Trends Report (2024), pharmaceutical companies raised their R&D spending by 49% from 2018 to 2023, reaching over USD 161 billion. Companies like J&J plan to launch 20 new drugs by 2030 to offset revenue declines. Additionally, rising biosimilar development is driving demand for CRO services, as generic and biosimilar manufacturers require outsourced clinical trials.
Restraint: High costs associated with clinical trial supplies
No restraints
Opportunity: Regulatory requirement for increasing diversity in clinical trials
Regulatory agencies like the FDA and EMA are increasing requirements for diversity in clinical trials to ensure treatments are effective for all populations. The FDA’s 2024 guidelines require trial sponsors to develop Diversity Action Plans (DAPs) to include underrepresented groups, while the EMA’s Clinical Trials Regulation (EU) No. 536/2014 promotes broader participant inclusion. To meet these requirements, pharmaceutical companies are expanding trials to new locations and partnering with local organizations, making trial management more complex. This is driving demand for CROs, which help with logistics, regulatory compliance, and patient recruitment. Many companies are also using decentralized trials and digital tools to improve accessibility.
Challenge: Cybersecurity or intellectual property concerns
Cybersecurity and intellectual property (IP) concerns are major challenges in the outsourced clinical trial market. Clinical trials involve large amounts of sensitive data, including patient information and drug development details. When trials are outsourced, this data is shared across multiple platforms, increasing the risk of cyberattacks, data breaches, and unauthorized access. Ransomware attacks and data leaks have become more common, threatening trial integrity and compliance with regulations. Intellectual property protection is also a concern, as outsourcing involves multiple partners in different countries, each following different data security rules.
clinical-trials-market: COMMERCIAL USE CASES ACROSS INDUSTRIES
| COMPANY | USE CASE DESCRIPTION | BENEFITS |
|---|---|---|
 |
ICON plc provided clinical trial services to the Pfizer and BioNTech SE investigational COVID-19 vaccine programme. | Provided high level of remote clinical monitoring and source data verification, safeguarding data quality and integrity in the evolving pandemic environment. |
Logos and trademarks shown above are the property of their respective owners. Their use here is for informational and illustrative purposes only.
MARKET ECOSYSTEM
The clinical trial services market ecosystem consists of raw material suppliers (clinical supply vendors, laboratory service providers, data and IT integrators), service and technology providers (CROs, specialized clinical trial management and site support firms), and end users (pharmaceutical and biotechnology sponsors, medical device companies, academic research networks). Key services span from protocol development and site management to patient recruitment, monitoring, biomarker analysis, data management, and regulatory submission, across all study phases (I-IV).
Logos and trademarks shown above are the property of their respective owners. Their use here is for informational and illustrative purposes only.
MARKET SEGMENTS
Source: Secondary Research, Interviews with Experts, MarketsandMarkets Analysis
Clinical Trial Services Market, By Services
In 2024, clinical trial management & monitoring services held the largest share of the market owing to the increasing integration of advanced technologies such as AI/ML and wearable devices supporting remote clinical monitoring. These services also help sponsors enhance their site contracting cycle times and site payments by negotiating and managing contracts with clinical trial sites and streamlining the payment process to clinical trial sites.
Clinical Trial Services Market, By Study design
In 2024, interventional studies dominated the clinical trial services market. This large share of this study design segment can be attributed to the rising demand for new drugs and medical devices for various therapy areas such as oncology, and neurology among others leading to an increased demand for interventional trials, as these therapies require stringent testing in controlled environments for approvals by regulatory bodies. Owing to this pharmaceutical companies and CROs invest in these studies to accelerate drug development and bring innovative therapies to market.
Clinical Trial Services Market, By Delivery Model
In 2024, the full-service outsourcing model held the largest share of the clinical trial services market due to the increase in the number of small and mid-size pharmaceutical companies that prefer the FSO service model as they have limited resources and rely on CRO’s expertise for conducting clinical trials. Moreover, large pharmaceutical companies also utilize FSO for late-stage trials, where extensive global site management and regulatory expertise are required.
REGION
Asia Pacific to be fastest-growing region in global clinical trial services market during forecast period
The Asia Pacific region is expected to grow at the highest rate during the forecast period, supported by availability of a diverse and vast patient population for clinical trials, rising government spending, and relatively low manufacturing costs.
clinical-trials-market: COMPANY EVALUATION MATRIX
In the clinical trial services market matrix, IQVIA (Star) leads with a dominant global market share and unmatched breadth of advanced technology, data, and service capabilities. IQVIA drives innovation with its integrated platform for decentralized and hybrid clinical trials, leveraging proprietary analytics, AI-driven trial management, and connected data solutions that help sponsors accelerate drug development, optimize patient recruitment, and ensure regulatory compliance across all phases. Pharmaron (Emerging Leader) is rapidly gaining international visibility by offering comprehensive, flexible clinical development services spanning early to late-stage studies, with a strong reputation in complex and adaptive trial designs.
Source: Secondary Research, Interviews with Experts, MarketsandMarkets Analysis
KEY MARKET PLAYERS
- IQVIA Inc. (US)
- Thermo Fisher Scientific Inc. (US)
- Fortrea (US)
- ICON Plc (Ireland)
- Medpace (US)
- Syneos Health (US)
- Laboratory Corporation of America Holdings (US)
- Wuxi AppTec (China)
- Frontage Labs (US)
- Pharmaron (US)
- Tigermed (China)
- SGS Société Générale De Surveillance SA. (Switzerland)
- Eurofins Scientific (Luxembourg)
- Linical (Japan)
- Parexel International Corporation (US)
- Worldwide Clinical Trials (US)
- Novotech (Australia)
- PSI (Switzerland)
- Allucent (US)
WHAT IS IN IT FOR YOU: clinical-trials-market REPORT CONTENT GUIDE
DELIVERED CUSTOMIZATIONS
We have successfully delivered the following deep-dive customizations:
| CLIENT REQUEST | CUSTOMIZATION DELIVERED | VALUE ADDS |
|---|---|---|
| Global Competitive Landscape Assessment |
|
|
| End-to-End Outsourcing Strategy |
|
|
RECENT DEVELOPMENTS
- February 2025 : Novotech signed an MOU with Wonju Severance Christian Hospital in South Korea to enhance clinical research and medical innovation by combining its expertise in clinical trial management with the hospital’s strong research capabilities to improve trial quality and patient care.
- Januay 2025 : ICON plc expanded its AI portfolio to improve clinical trial efficiencies, supported by its AI Centre of Excellence and AI Governance Committee. The newly launched AI tools include iSubmit for automating clinical trial document management, Mapi Research Trust COA for real-time updates on Clinical Outcome Assessments, FORWARD+ for resource demand forecasting, Study Startup Site Contracts for streamlining contract drafting, and OMR AI Navigation Assistant for advanced clinical study analytics.
- December 2024 : PPD renewed two contracts with the US National Institutes of Health (NIH) focusing on monitoring clinical trial sites and providing research support for HIV and related diseases.
Table of Contents
Exclusive indicates content/data unique to MarketsandMarkets and not available with any competitors.
TITLE
PAGE NO
1
INTRODUCTION
31
2
RESEARCH METHODOLOGY
35
3
EXECUTIVE SUMMARY
47
4
PREMIUM INSIGHTS
52
5
MARKET OVERVIEW
Explore market growth driven by R&D investments and decentralized trials amidst regulatory challenges.
56
5.1
INTRODUCTION
5.2
MARKET DYNAMICS
5.2.1
DRIVERS
5.2.1.1
INCREASING NUMBER OF CLINICAL TRIALS
5.2.1.2
RISING INVESTMENTS IN RESEARCH & DEVELOPMENT
5.2.1.3
GROWING PREVALENCE OF RARE DISEASES
5.2.1.4
FAVORABLE GOVERNMENT INITIATIVES
5.2.2
RESTRAINTS
5.2.2.1
HIGH COSTS ASSOCIATED WITH CLINICAL TRIALS
5.2.2.2
SHORTAGE OF SKILLED PROFESSIONALS
5.2.3
OPPORTUNITIES
5.2.3.1
EMERGING MARKETS WORLDWIDE
5.2.3.2
DECENTRALIZED AND VIRTUAL CLINICAL TRIALS
5.2.4
CHALLENGES
5.2.4.1
REGULATORY COMPLEXITIES
5.2.4.2
LIMITED PATIENT DIVERSITY
5.2.4.3
CYBERSECURITY AND INTELLECTUAL PROPERTY CONCERNS
5.3
TRENDS/DISRUPTIONS IMPACTING CUSTOMER BUSINESS
5.4
VALUE CHAIN ANALYSIS
5.4.1
RESOURCE ACQUISITION AND PREPARATION
5.4.2
CLINICAL TRIAL EXECUTION
5.4.3
DATA REPORTING AND RESULT SUBMISSION
5.4.4
PROMOTION AND REGULATORY FILING
5.5
ECOSYSTEM ANALYSIS
5.6
INVESTMENT AND FUNDING SCENARIO
5.7
TECHNOLOGY ANALYSIS
5.7.1
KEY TECHNOLOGIES
5.7.1.1
ENZYME-LINKED IMMUNOSORBENT ASSAY
5.7.2
ADJACENT TECHNOLOGIES
5.7.2.1
NEXT-GENERATION SEQUENCING
5.8
KEY CONFERENCES AND EVENTS, 2025–2026
5.9
CASE STUDY ANALYSIS
5.9.1
PHASE 3 CLINICAL TRIAL TO COMPARE EFFICACY AND SAFETY OF TWO COMBINATION THERAPIES (CERBA RESEARCH)
5.10
REGULATORY LANDSCAPE
5.10.1
REGULATORY FRAMEWORK
5.10.1.1
NORTH AMERICA
5.10.1.2
EUROPE
5.10.1.3
ASIA PACIFIC
5.10.1.4
REST OF THE WORLD
5.10.2
REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
5.11
PORTER’S FIVE FORCES ANALYSIS
5.11.1
THREAT OF NEW ENTRANTS
5.11.2
THREAT OF SUBSTITUTES
5.11.3
BARGAINING POWER OF SUPPLIERS
5.11.4
BARGAINING POWER OF BUYERS
5.11.5
INTENSITY OF COMPETITIVE RIVALRY
5.12
KEY STAKEHOLDERS AND BUYING CRITERIA
5.12.1
KEY STAKEHOLDERS IN BUYING PROCESS
5.12.2
BUYING CRITERIA
5.13
IMPACT OF AI/GENERATIVE AI ON CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET
5.13.1
INTRODUCTION
5.13.2
MARKET POTENTIAL OF CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES
5.13.3
AI USE CASES
5.13.4
FUTURE OF GENERATIVE AI IN CLINICAL TRIAL LAB ECOSYSTEM
6
CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET, BY PHASE
Market Size & Growth Rate Forecast Analysis to 2030 in USD Million | 21 Data Tables
88
6.1
INTRODUCTION
6.2
PHASE I
6.2.1
NEED TO ASSESS SAFETY, DOSAGE, AND POTENTIAL SIDE EFFECTS OF DRUGS TO AID GROWTH
6.3
PHASE II
6.3.1
NEED TO EVALUATE DESIRED EFFECT AND ADDITIONAL SAFETY DATA OF DRUGS TO DRIVE MARKET
6.4
PHASE III
6.4.1
RISING INCLINATION TOWARD CONFIRMING SAFETY AND EFFICACY OF DRUGS TO BOOST MARKET
6.5
PHASE IV
6.5.1
ONGOING SAFETY SURVEILLANCE ON DRUG TRIALS TO AUGMENT GROWTH
7
CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET, BY SERVICE TYPE
Market Size & Growth Rate Forecast Analysis to 2030 in USD Million | 33 Data Tables
100
7.1
INTRODUCTION
7.2
SAFETY TESTING
7.2.1
NEED TO ENSURE COMPLIANCE WITH SAFETY STANDARDS TO PROMOTE GROWTH
7.3
IMMUNOLOGY
7.3.1
INCREASING FOCUS ON IMMUNOTHERAPIES TO STIMULATE GROWTH
7.4
GENETIC TESTING
7.4.1
GROWING ADVANCEMENTS IN NEXT-GENERATION SEQUENCING TO DRIVE MARKET
7.5
COAGULATION TESTING
7.5.1
ESSENTIAL ROLE IN MONITORING COAGULATION DISORDERS AND EVALUATING ANTICOAGULANT THERAPIES TO EXPEDITE GROWTH
7.6
PATHOLOGY TESTING
7.6.1
ABILITY TO PROVIDE INSIGHTS INTO DISEASE MECHANISMS, TREATMENT EFFECTS, AND DIAGNOSTICS TO AID GROWTH
7.7
BIOMARKERS
7.7.1
NEED TO EXAMINE TEST EFFECTS ON PATIENTS TO AUGMENT GROWTH
7.8
COMPANION DIAGNOSTICS
7.8.1
GROWING INCLINATION TOWARD PERSONALIZED TREATMENTS TO DRIVE MARKET
7.9
OTHER TESTS
8
CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET, BY THERAPEUTIC AREA
Market Size & Growth Rate Forecast Analysis to 2030 in USD Million | 21 Data Tables
118
8.1
INTRODUCTION
8.2
ONCOLOGY
8.2.1
INCREASING CANCER RESEARCH STUDIES TO ACCELERATE GROWTH
8.3
INFECTIOUS DISEASES
8.3.1
INCREASING CASES OF INFECTIOUS DISEASES TO ENCOURAGE GROWTH
8.4
NEUROLOGY
8.4.1
RISING PREVALENCE OF NEUROLOGICAL DISORDERS TO FACILITATE GROWTH
8.5
CARDIOLOGY
8.5.1
GROWING INCIDENCE OF CARDIOVASCULAR DISEASES TO PROPEL MARKET
8.6
OTHER THERAPEUTIC AREAS
9
CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET, BY MODALITY
Market Size & Growth Rate Forecast Analysis to 2030 in USD Million | 30 Data Tables
131
9.1
INTRODUCTION
9.2
SMALL MOLECULES
9.2.1
EMERGENCE OF THERAPEUTIC MODALITIES TO AMPLIFY GROWTH
9.3
BIOLOGICS
9.3.1
MONOCLONAL ANTIBODIES
9.3.1.1
GROWING ADVANCEMENTS IN ANTIBODY ENGINEERING TO DRIVE MARKET
9.3.2
VACCINES
9.3.2.1
INCREASING INVESTMENTS IN VACCINE DEVELOPMENT TO FAVOR GROWTH
9.3.3
OTHER THERAPEUTIC PRODUCTS
9.4
CELL & GENE THERAPY
9.4.1
OUTSOURCING TREND TO FAVOR GROWTH
9.5
MEDICAL DEVICES & IVD DEVICES
9.5.1
RISING FOCUS ON REAL-TIME PATIENT HEALTH TRACKING TO BOOST MARKET
10
CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET, BY END USER
Market Size & Growth Rate Forecast Analysis to 2030 in USD Million | 17 Data Tables
147
10.1
INTRODUCTION
10.2
PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES
10.2.1
EMERGING BIOPHARMA COMPANIES TO EXPEDITE GROWTH
10.3
CLINICAL RESEARCH ORGANIZATIONS
10.3.1
CRITICAL ROLE IN SITE SELECTION, RECRUITMENT SUPPORT, CLINICAL MONITORING, AND DATA COLLECTION TO DRIVE MARKET
10.4
MEDICAL DEVICE COMPANIES
10.4.1
RISING FOCUS ON QUALITY AND SAFETY STANDARDS TO STIMULATE GROWTH
10.5
OTHER END USERS
11
CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET, BY REGION
Comprehensive coverage of 7 Regions with country-level deep-dive of 10 Countries | 111 Data Tables.
157
11.1
INTRODUCTION
11.2
NORTH AMERICA
11.2.1
MACROECONOMIC OUTLOOK FOR NORTH AMERICA
11.2.2
US
11.2.2.1
INCREASING CLINICAL TRIALS TO SUPPORT GROWTH
11.2.3
CANADA
11.2.3.1
RISING INCIDENCE OF CHRONIC DISEASES TO ADVANCE GROWTH
11.3
EUROPE
11.3.1
MACROECONOMIC OUTLOOK FOR EUROPE
11.3.2
GERMANY
11.3.2.1
INCREASING HEALTHCARE EXPENDITURE TO INTENSIFY GROWTH
11.3.3
FRANCE
11.3.3.1
GROWING INVESTMENTS IN LIFE SCIENCES SECTOR TO BOOST MARKET
11.3.4
UK
11.3.4.1
HIGH NUMBER OF ONCOLOGY CLINICAL TRIALS TO FACILITATE GROWTH
11.3.5
ITALY
11.3.5.1
RISING FOCUS ON STREAMLINING CLINICAL TRIAL PROCESS TO EXPEDITE GROWTH
11.3.6
SPAIN
11.3.6.1
EMERGING BIOTECH COMPANIES TO BOLSTER GROWTH
11.3.7
REST OF EUROPE
11.4
ASIA PACIFIC
11.4.1
MACROECONOMIC OUTLOOK FOR ASIA PACIFIC
11.4.2
JAPAN
11.4.2.1
GROWING DEMAND FOR DRUG DEVELOPMENT TO PROPEL MARKET
11.4.3
CHINA
11.4.3.1
BOOMING PHARMACEUTICAL INDUSTRY TO DRIVE MARKET
11.4.4
INDIA
11.4.4.1
INCREASING REGULATORY REFORMS TO FOSTER GROWTH
11.4.5
REST OF ASIA PACIFIC
11.5
LATIN AMERICA
11.5.1
ROBUST MANUFACTURING INFRASTRUCTURE TO SUSTAIN GROWTH
11.5.2
MACROECONOMIC OUTLOOK FOR LATIN AMERICA
11.6
MIDDLE EAST & AFRICA
11.6.1
GROWING DEMAND FOR OUTSOURCING SERVICES TO FUEL MARKET
11.6.2
MACROECONOMIC OUTLOOK FOR MIDDLE EAST & AFRICA
12
COMPETITIVE LANDSCAPE
Uncover market leaders' strategies and financial metrics shaping the clinical trial lab services landscape.
229
12.1
OVERVIEW
12.2
KEY PLAYER STRATEGIES/RIGHT TO WIN
12.2.1
OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS IN CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET
12.3
REVENUE ANALYSIS, 2020−2024
12.4
MARKET SHARE ANALYSIS, 2024
12.5
COMPANY VALUATION AND FINANCIAL METRICS
12.6
BRAND/PRODUCT COMPARISON
12.7
COMPANY EVALUATION MATRIX: KEY PLAYERS, 2024
12.7.1
STARS
12.7.2
EMERGING LEADERS
12.7.3
PERVASIVE PLAYERS
12.7.4
PARTICIPANTS
12.7.5
COMPANY FOOTPRINT: KEY PLAYERS, 2024
12.7.5.1
COMPANY FOOTPRINT
12.7.5.2
REGION FOOTPRINT
12.7.5.3
PRODUCT TYPE FOOTPRINT
12.7.5.4
THERAPEUTIC AREA FOOTPRINT
12.7.5.5
PHASE FOOTPRINT
12.8
COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2024
12.8.1
PROGRESSIVE COMPANIES
12.8.2
RESPONSIVE COMPANIES
12.8.3
DYNAMIC COMPANIES
12.8.4
STARTING BLOCKS
12.8.5
COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2024
12.8.5.1
DETAILED LIST OF KEY STARTUPS/SMES
12.8.5.2
COMPETITIVE BENCHMARKING OF KEY STARTUPS/SMES
12.9
COMPETITIVE SCENARIO
12.9.1
PRODUCT LAUNCHES
12.9.2
DEALS
12.9.3
EXPANSIONS
12.9.4
OTHER DEVELOPMENTS
13
COMPANY PROFILES
In-depth Company Profiles of Leading Market Players with detailed Business Overview, Product and Service Portfolio, Recent Developments, and Unique Analyst Perspective (MnM View)
251
13.1
KEY PLAYERS
13.1.1
THERMO FISHER SCIENTIFIC INC.
13.1.1.1
BUSINESS OVERVIEW
13.1.1.2
PRODUCTS/SERVICES OFFERED
13.1.1.3
RECENT DEVELOPMENTS
13.1.1.3.1
PRODUCT LAUNCHES
13.1.1.3.2
DEALS
13.1.1.3.3
EXPANSIONS
13.1.1.4
MNM VIEW
13.1.1.4.1
KEY STRENGTHS
13.1.1.4.2
STRATEGIC CHOICES
13.1.1.4.3
WEAKNESSES AND COMPETITIVE THREATS
13.1.2
IQVIA
13.1.3
ICON PLC
13.1.4
CHARLES RIVER LABORATORIES
13.1.5
LABCORP
13.1.6
QUEST DIAGNOSTICS
13.1.7
MEDPACE
13.1.8
FRONTAGE LABS
13.1.9
SGS SOCIÉTÉ GÉNÉRALE DE SURVEILLANCE SA
13.1.10
EUROFINS SCIENTIFIC
13.1.11
REPROCELL INC.
13.1.12
ACM GLOBAL LABORATORIES
13.2
OTHER PLAYERS
13.2.1
WORLDWIDE CLINICAL TRIALS
13.2.2
VERSITI
13.2.3
CTI CLINICAL TRIAL & CONSULTING
13.2.4
CLARITY LABORATORIES, INC
13.2.5
NOVOTECH
13.2.6
ARUP LABORATORIES
13.2.7
PRECISION MEDICINE GROUP
13.2.8
BIOAGILYTIX LABS
13.2.9
CERBA HEALTHCARE
13.2.10
ALMAC GROUP
13.2.11
MLM MEDICAL LABS
13.2.12
SALVUS BIORESEARCH SOLUTIONS LLP
13.2.13
UNILABS
14
APPENDIX
302
14.1
DISCUSSION GUIDE
14.2
KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
14.3
CUSTOMIZATION OPTIONS
14.4
RELATED REPORTS
14.5
AUTHOR DETAILS
LIST OF TABLES
TABLE 1
CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET: INCLUSIONS AND EXCLUSIONS
TABLE 2
CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET: RISK ASSESSMENT
TABLE 3
TRADITIONAL VS. VIRTUAL CLINICAL TRIALS
TABLE 4
CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET: ROLE OF COMPANIES IN ECOSYSTEM
TABLE 5
CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET: KEY CONFERENCES AND EVENTS, 2025−2026
TABLE 6
NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 7
EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 8
ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 9
LATIN AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 10
MIDDLE EAST & AFRICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 11
REGULATORY SCENARIO FOR DRUG APPROVALS AND CGMP PROCEDURES
TABLE 12
CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET: PORTER’S FIVE FORCES ANALYSIS
TABLE 13
INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS, BY END USER (%)
TABLE 14
KEY BUYING CRITERIA, BY END USER
TABLE 15
KEY COMPANIES IMPLEMENTING AI
TABLE 16
CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET, BY PHASE, 2022–2030 (USD MILLION)
TABLE 18
COMPANIES PROVIDING PHASE I SERVICES
TABLE 19
CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET FOR PHASE I, BY REGION, 2022–2030 (USD MILLION)
TABLE 20
NORTH AMERICA: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET FOR PHASE I SERVICES, BY COUNTRY, 2022–2030 (USD MILLION)
TABLE 22
EUROPE: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET FOR PHASE I SERVICES, BY COUNTRY, 2022–2030 (USD MILLION)
TABLE 23
ASIA PACIFIC: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET FOR PHASE I SERVICES, BY COUNTRY, 2022–2030 (USD MILLION)
TABLE 24
COMPANIES PROVIDING PHASE II SERVICES
TABLE 25
CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET FOR PHASE II SERVICES, BY REGION, 2022–2030 (USD MILLION)
TABLE 26
NORTH AMERICA: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET FOR PHASE II SERVICES, BY COUNTRY, 2022–2030 (USD MILLION)
TABLE 27
EUROPE: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET FOR PHASE II SERVICES, BY COUNTRY, 2022–2030 (USD MILLION)
TABLE 28
ASIA PACIFIC: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET FOR PHASE II SERVICES, BY COUNTRY, 2022–2030 (USD MILLION)
TABLE 29
COMPANIES PROVIDING PHASE III SERVICES
TABLE 30
CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET FOR PHASE III SERVICES, BY REGION, 2022–2030 (USD MILLION)
TABLE 31
NORTH AMERICA: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET FOR PHASE III SERVICES, BY COUNTRY, 2022–2030 (USD MILLION)
TABLE 32
EUROPE: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET FOR PHASE III SERVICES, BY COUNTRY, 2022–2030 (USD MILLION)
TABLE 33
ASIA PACIFIC: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET FOR PHASE III SERVICES, BY COUNTRY, 2022–2030 (USD MILLION)
TABLE 34
COMPANIES PROVIDING PHASE IV SERVICES
TABLE 35
CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET FOR PHASE IV SERVICES, BY REGION, 2022–2030 (USD MILLION)
TABLE 36
NORTH AMERICA: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET FOR PHASE IV SERVICES, BY COUNTRY, 2022–2030 (USD MILLION)
TABLE 37
EUROPE: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET FOR PHASE IV SERVICES, BY COUNTRY, 2022–2030 (USD MILLION)
TABLE 38
ASIA PACIFIC: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET FOR PHASE IV SERVICES, BY COUNTRY, 2022–2030 (USD MILLION)
TABLE 39
CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET, BY SERVICE TYPE, 2022–2030 (USD MILLION)
TABLE 40
CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET FOR SAFETY TESTING, BY REGION, 2022–2030 (USD MILLION)
TABLE 41
NORTH AMERICA: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET FOR SAFETY TESTING, BY COUNTRY, 2022–2030 (USD MILLION)
TABLE 42
EUROPE: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET FOR SAFETY TESTING, BY COUNTRY, 2022–2030 (USD MILLION)
TABLE 43
ASIA PACIFIC: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET FOR SAFETY TESTING, BY COUNTRY, 2022–2030 (USD MILLION)
TABLE 44
CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET FOR IMMUNOLOGY, BY REGION, 2022–2030 (USD MILLION)
TABLE 45
NORTH AMERICA: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET FOR IMMUNOLOGY, BY COUNTRY, 2022–2030 (USD MILLION)
TABLE 46
EUROPE: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET FOR IMMUNOLOGY, BY COUNTRY, 2022–2030 (USD MILLION)
TABLE 47
ASIA PACIFIC: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET FOR IMMUNOLOGY, BY COUNTRY, 2022–2030 (USD MILLION)
TABLE 48
CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET FOR GENETIC TESTING, BY REGION, 2022–2030 (USD MILLION)
TABLE 49
NORTH AMERICA: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET FOR GENETIC TESTING, BY COUNTRY, 2022–2030 (USD MILLION)
TABLE 50
EUROPE: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET FOR GENETIC TESTING, BY COUNTRY, 2022–2030 (USD MILLION)
TABLE 51
ASIA PACIFIC: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET FOR GENETIC TESTING, BY COUNTRY, 2022–2030 (USD MILLION)
TABLE 52
CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET FOR COAGULATION TESTING, BY REGION, 2022–2030 (USD MILLION)
TABLE 53
NORTH AMERICA: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET FOR COAGULATION TESTING, BY COUNTRY, 2022–2030 (USD MILLION)
TABLE 54
EUROPE: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET FOR COAGULATION TESTING, BY COUNTRY, 2022–2030 (USD MILLION)
TABLE 55
ASIA PACIFIC: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET FOR COAGULATION TESTING, BY COUNTRY, 2022–2030 (USD MILLION)
TABLE 56
CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET FOR PATHOLOGY TESTING, BY REGION, 2022–2030 (USD MILLION)
TABLE 57
NORTH AMERICA: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET FOR PATHOLOGY TESTING, BY COUNTRY, 2022–2030 (USD MILLION)
TABLE 58
EUROPE: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET FOR PATHOLOGY TESTING, BY COUNTRY, 2022–2030 (USD MILLION)
TABLE 59
ASIA PACIFIC: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET FOR PATHOLOGY TESTING, BY COUNTRY, 2022–2030 (USD MILLION)
TABLE 60
CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET FOR BIOMARKERS, BY REGION, 2022–2030 (USD MILLION)
TABLE 61
NORTH AMERICA: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET FOR BIOMARKERS, BY COUNTRY, 2022–2030 (USD MILLION)
TABLE 62
EUROPE: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET FOR BIOMARKERS, BY COUNTRY, 2022–2030 (USD MILLION)
TABLE 63
ASIA PACIFIC: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET FOR BIOMARKERS, BY COUNTRY, 2022–2030 (USD MILLION)
TABLE 64
CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET FOR COMPANION DIAGNOSTICS, BY REGION, 2022–2030 (USD MILLION)
TABLE 65
NORTH AMERICA: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET FOR COMPANION DIAGNOSTICS, BY COUNTRY, 2022–2030 (USD MILLION)
TABLE 66
EUROPE: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET FOR COMPANION DIAGNOSTICS, BY COUNTRY, 2022–2030 (USD MILLION)
TABLE 67
ASIA PACIFIC: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET FOR COMPANION DIAGNOSTICS, BY COUNTRY, 2022–2030 (USD MILLION)
TABLE 68
CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET FOR OTHER TESTS, BY REGION, 2022–2030 (USD MILLION)
TABLE 69
NORTH AMERICA: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET FOR OTHER TESTS, BY COUNTRY, 2022–2030 (USD MILLION)
TABLE 70
EUROPE: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET FOR OTHER TESTS, BY COUNTRY, 2022–2030 (USD MILLION)
TABLE 71
ASIA PACIFIC: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET FOR OTHER TESTS, BY COUNTRY, 2022–2030 (USD MILLION)
TABLE 72
CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET, BY THERAPEUTIC AREA, 2022–2030 (USD MILLION)
TABLE 73
CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET FOR ONCOLOGY, BY REGION, 2022–2030 (USD MILLION)
TABLE 74
NORTH AMERICA: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET FOR ONCOLOGY, BY COUNTRY, 2022–2030 (USD MILLION)
TABLE 75
EUROPE: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET FOR ONCOLOGY, BY COUNTRY, 2022–2030 (USD MILLION)
TABLE 76
ASIA PACIFIC: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET FOR ONCOLOGY, BY COUNTRY, 2022–2030 (USD MILLION)
TABLE 77
CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET FOR INFECTIOUS DISEASES, BY REGION, 2022–2030 (USD MILLION)
TABLE 78
NORTH AMERICA: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2022–2030 (USD MILLION)
TABLE 79
EUROPE: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2022–2030 (USD MILLION)
TABLE 80
ASIA PACIFIC: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2022–2030 (USD MILLION)
TABLE 81
CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET FOR NEUROLOGY, BY REGION, 2022–2030 (USD MILLION)
TABLE 82
NORTH AMERICA: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET FOR NEUROLOGY, BY COUNTRY, 2022–2030 (USD MILLION)
TABLE 83
EUROPE: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET FOR NEUROLOGY, BY COUNTRY, 2022–2030 (USD MILLION)
TABLE 84
ASIA PACIFIC: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET FOR NEUROLOGY, BY COUNTRY, 2022–2030 (USD MILLION)
TABLE 85
CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET FOR CARDIOLOGY, BY REGION, 2022–2030 (USD MILLION)
TABLE 86
NORTH AMERICA: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET FOR CARDIOLOGY, BY COUNTRY, 2022–2030 (USD MILLION)
TABLE 87
EUROPE: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET FOR CARDIOLOGY, BY COUNTRY, 2022–2030 (USD MILLION)
TABLE 88
ASIA PACIFIC: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET FOR CARDIOLOGY, BY COUNTRY, 2022–2030 (USD MILLION)
TABLE 89
CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET FOR OTHER THERAPEUTIC AREAS, BY REGION, 2022–2030 (USD MILLION)
TABLE 90
NORTH AMERICA: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET FOR OTHER THERAPEUTIC AREAS, BY COUNTRY, 2022–2030 (USD MILLION)
TABLE 91
EUROPE: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET FOR OTHER THERAPEUTIC AREAS, BY COUNTRY, 2022–2030 (USD MILLION)
TABLE 92
ASIA PACIFIC: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET FOR OTHER THERAPEUTIC AREAS, BY COUNTRY, 2022–2030 (USD MILLION)
TABLE 93
CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET, BY MODALITY, 2022–2030 (USD MILLION)
TABLE 94
CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET FOR SMALL MOLECULES, BY REGION, 2022–2030 (USD MILLION)
TABLE 95
NORTH AMERICA: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET FOR SMALL MOLECULES, BY COUNTRY, 2022–2030 (USD MILLION)
TABLE 96
EUROPE: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET FOR SMALL MOLECULES, BY COUNTRY, 2022–2030 (USD MILLION)
TABLE 97
ASIA PACIFIC: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET FOR SMALL MOLECULES, BY COUNTRY, 2022–2030 (USD MILLION)
TABLE 98
CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET, BY BIOLOGICS, 2022–2030 (USD MILLION)
TABLE 99
CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET FOR BIOLOGICS, BY REGION, 2022–2030 (USD MILLION)
TABLE 100
NORTH AMERICA: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET FOR BIOLOGICS, BY COUNTRY, 2022–2030 (USD MILLION)
TABLE 101
EUROPE: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET FOR BIOLOGICS, BY COUNTRY, 2022–2030 (USD MILLION)
TABLE 102
ASIA PACIFIC: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET FOR BIOLOGICS, BY COUNTRY, 2022–2030 (USD MILLION)
TABLE 103
CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET FOR MONOCLONAL ANTIBODIES, BY REGION, 2022–2030 (USD MILLION)
TABLE 104
NORTH AMERICA: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET FOR MONOCLONAL ANTIBODIES, BY COUNTRY, 2022–2030 (USD MILLION)
TABLE 105
EUROPE: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET FOR MONOCLONAL ANTIBODIES, BY COUNTRY, 2022–2030 (USD MILLION)
TABLE 106
ASIA PACIFIC: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET FOR MONOCLONAL ANTIBODIES, BY COUNTRY, 2022–2030 (USD MILLION)
TABLE 107
CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET FOR VACCINES, BY REGION, 2022–2030 (USD MILLION)
TABLE 108
NORTH AMERICA: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET FOR VACCINES, BY COUNTRY, 2022–2030 (USD MILLION)
TABLE 109
EUROPE: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET FOR VACCINES, BY COUNTRY, 2022–2030 (USD MILLION)
TABLE 110
ASIA PACIFIC: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET FOR VACCINES, BY COUNTRY, 2022–2030 (USD MILLION)
TABLE 111
CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET FOR OTHER THERAPEUTIC PRODUCTS, BY REGION, 2022–2030 (USD MILLION)
TABLE 112
NORTH AMERICA: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET FOR OTHER THERAPEUTIC PRODUCTS, BY COUNTRY, 2022–2030 (USD MILLION)
TABLE 113
EUROPE: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET FOR OTHER THERAPEUTIC PRODUCTS, BY COUNTRY, 2022–2030 (USD MILLION)
TABLE 114
ASIA PACIFIC: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET FOR OTHER THERAPEUTIC PRODUCTS, BY COUNTRY, 2022–2030 (USD MILLION)
TABLE 115
CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET FOR CELL & GENE THERAPY, BY REGION, 2022–2030 (USD MILLION)
TABLE 116
NORTH AMERICA: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET FOR CELL & GENE THERAPY, BY COUNTRY, 2022–2030 (USD MILLION)
TABLE 117
EUROPE: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET FOR CELL & GENE THERAPY, BY COUNTRY, 2022–2030 (USD MILLION)
TABLE 118
ASIA PACIFIC: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET FOR CELL & GENE THERAPY, BY COUNTRY, 2022–2030 (USD MILLION)
TABLE 119
CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET FOR MEDICAL DEVICES & IVD DEVICES, BY REGION, 2022–2030 (USD MILLION)
TABLE 120
NORTH AMERICA: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET FOR MEDICAL DEVICES & IVD DEVICES, BY COUNTRY, 2022–2030 (USD MILLION)
TABLE 121
EUROPE: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET FOR MEDICAL DEVICES & IVD DEVICES, BY COUNTRY, 2022–2030 (USD MILLION)
TABLE 122
ASIA PACIFIC: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET FOR MEDICAL DEVICES & IVD DEVICES, BY COUNTRY, 2022–2030 (USD MILLION)
TABLE 123
CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET, BY END USER, 2022–2030 (USD MILLION)
TABLE 124
CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET FOR PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES, BY REGION, 2022–2030 (USD MILLION)
TABLE 125
NORTH AMERICA: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET FOR PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES, BY COUNTRY, 2022–2030 (USD MILLION)
TABLE 126
EUROPE: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET FOR PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES, BY COUNTRY, 2022–2030 (USD MILLION)
TABLE 127
ASIA PACIFIC: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET FOR PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES, BY COUNTRY, 2022–2030 (USD MILLION)
TABLE 128
CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET FOR CROS, BY REGION, 2022–2030 (USD MILLION)
TABLE 129
NORTH AMERICA: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET FOR CROS, BY COUNTRY, 2022–2030 (USD MILLION)
TABLE 130
EUROPE: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET FOR CROS, BY COUNTRY, 2022–2030 (USD MILLION)
TABLE 131
ASIA PACIFIC: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET FOR CROS, BY COUNTRY, 2022–2030 (USD MILLION)
TABLE 132
CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET FOR MEDICAL DEVICE COMPANIES, BY REGION, 2022–2030 (USD MILLION)
TABLE 133
NORTH AMERICA: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET FOR MEDICAL DEVICE COMPANIES, BY COUNTRY, 2022–2030 (USD MILLION)
TABLE 134
EUROPE: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET FOR MEDICAL DEVICE COMPANIES, BY COUNTRY, 2022–2030 (USD MILLION)
TABLE 135
ASIA PACIFIC: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET FOR MEDICAL DEVICE COMPANIES, BY COUNTRY, 2022–2030 (USD MILLION)
TABLE 136
CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET FOR OTHER END USERS, BY REGION, 2022–2030 (USD MILLION)
TABLE 137
NORTH AMERICA: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET FOR OTHER END USERS, BY COUNTRY, 2022–2030 (USD MILLION)
TABLE 138
EUROPE: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET FOR OTHER END USERS, BY COUNTRY, 2022–2030 (USD MILLION)
TABLE 139
ASIA PACIFIC: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET FOR OTHER END USERS, BY COUNTRY, 2022–2030 (USD MILLION)
TABLE 140
CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET, BY REGION, 2022–2030 (USD MILLION)
TABLE 141
MACROECONOMIC INDICATORS FOR NORTH AMERICA
TABLE 142
NORTH AMERICA: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET, BY COUNTRY, 2022–2030 (USD MILLION)
TABLE 143
NORTH AMERICA: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET, BY PHASE, 2022–2030 (USD MILLION)
TABLE 144
NORTH AMERICA: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET, BY SERVICE TYPE, 2022–2030 (USD MILLION)
TABLE 145
NORTH AMERICA: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET, BY THERAPEUTIC AREA, 2022–2030 (USD MILLION)
TABLE 146
NORTH AMERICA: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET, BY MODALITY, 2022–2030 (USD MILLION)
TABLE 147
NORTH AMERICA: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET, BY BIOLOGICS, 2022–2030 (USD MILLION)
TABLE 148
NORTH AMERICA: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET, BY END USER, 2022–2030 (USD MILLION)
TABLE 149
US: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET, BY PHASE, 2022–2030 (USD MILLION)
TABLE 150
US: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET, BY SERVICE TYPE, 2022–2030 (USD MILLION)
TABLE 151
US: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET, BY THERAPEUTIC AREA, 2022–2030 (USD MILLION)
TABLE 152
US: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET, BY MODALITY, 2022–2030 (USD MILLION)
TABLE 153
US: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET, BY BIOLOGICS, 2022–2030 (USD MILLION)
TABLE 154
US: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET, BY END USER, 2022–2030 (USD MILLION)
TABLE 155
CANADA: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET, BY PHASE, 2022–2030 (USD MILLION)
TABLE 156
CANADA: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET, BY SERVICE TYPE, 2022–2030 (USD MILLION)
TABLE 157
CANADA: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET, BY THERAPEUTIC AREA, 2022–2030 (USD MILLION)
TABLE 158
CANADA: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET, BY MODALITY, 2022–2030 (USD MILLION)
TABLE 159
CANADA: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET, BY BIOLOGICS, 2022–2030 (USD MILLION)
TABLE 160
CANADA: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET, BY END USER, 2022–2030 (USD MILLION)
TABLE 161
MACROECONOMIC INDICATORS FOR EUROPE
TABLE 162
EUROPE: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET, BY COUNTRY, 2022–2030 (USD MILLION)
TABLE 163
EUROPE: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET, BY PHASE, 2022–2030 (USD MILLION)
TABLE 164
EUROPE: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET, BY SERVICE TYPE, 2022–2030 (USD MILLION)
TABLE 165
EUROPE: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET, BY THERAPEUTIC AREA, 2022–2030 (USD MILLION)
TABLE 166
EUROPE: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET, BY MODALITY, 2022–2030 (USD MILLION)
TABLE 167
EUROPE: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET, BY BIOLOGICS, 2022–2030 (USD MILLION)
TABLE 168
EUROPE: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET, BY END USER, 2022–2030 (USD MILLION)
TABLE 169
GERMANY: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET, BY PHASE, 2022–2030 (USD MILLION)
TABLE 170
GERMANY: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET, BY SERVICE TYPE, 2022–2030 (USD MILLION)
TABLE 171
GERMANY: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET, BY THERAPEUTIC AREA, 2022–2030 (USD MILLION)
TABLE 172
GERMANY: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET, BY MODALITY, 2022–2030 (USD MILLION)
TABLE 173
GERMANY: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET, BY BIOLOGICS, 2022–2030 (USD MILLION)
TABLE 174
GERMANY: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET, BY END USER, 2022–2030 (USD MILLION)
TABLE 175
FRANCE: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET, BY PHASE, 2022–2030 (USD MILLION)
TABLE 176
FRANCE: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET, BY SERVICE TYPE, 2022–2030 (USD MILLION)
TABLE 177
FRANCE: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET, BY THERAPEUTIC AREA, 2022–2030 (USD MILLION)
TABLE 178
FRANCE: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET, BY MODALITY, 2022–2030 (USD MILLION)
TABLE 179
FRANCE: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET, BY BIOLOGICS, 2022–2030 (USD MILLION)
TABLE 180
FRANCE: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET, BY END USER, 2022–2030 (USD MILLION)
TABLE 181
UK: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET, BY PHASE, 2022–2030 (USD MILLION)
TABLE 182
UK: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET, BY SERVICE TYPE, 2022–2030 (USD MILLION)
TABLE 183
UK: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET, BY THERAPEUTIC AREA, 2022–2030 (USD MILLION)
TABLE 184
UK: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET, BY MODALITY, 2022–2030 (USD MILLION)
TABLE 185
UK: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET, BY BIOLOGICS, 2022–2030 (USD MILLION)
TABLE 186
UK: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET, BY END USER, 2022–2030 (USD MILLION)
TABLE 187
ITALY: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET, BY PHASE, 2022–2030 (USD MILLION)
TABLE 188
ITALY: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET, BY SERVICE TYPE, 2022–2030 (USD MILLION)
TABLE 189
ITALY: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET, BY THERAPEUTIC AREA, 2022–2030 (USD MILLION)
TABLE 190
ITALY: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET, BY MODALITY, 2022–2030 (USD MILLION)
TABLE 191
ITALY: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET, BY BIOLOGICS, 2022–2030 (USD MILLION)
TABLE 192
ITALY: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET, BY END USER, 2022–2030 (USD MILLION)
TABLE 193
SPAIN: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET, BY PHASE, 2022–2030 (USD MILLION)
TABLE 194
SPAIN: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET, BY SERVICE TYPE, 2022–2030 (USD MILLION)
TABLE 195
SPAIN: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET, BY THERAPEUTIC AREA, 2022–2030 (USD MILLION)
TABLE 196
SPAIN: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET, BY MODALITY, 2022–2030 (USD MILLION)
TABLE 197
SPAIN: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET, BY BIOLOGICS, 2022–2030 (USD MILLION)
TABLE 198
SPAIN: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET, BY END USER, 2022–2030 (USD MILLION)
TABLE 199
REST OF EUROPE: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET, BY PHASE, 2022–2030 (USD MILLION)
TABLE 200
REST OF EUROPE: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET, BY SERVICE TYPE, 2022–2030 (USD MILLION)
TABLE 201
REST OF EUROPE: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET, BY THERAPEUTIC AREA, 2022–2030 (USD MILLION)
TABLE 202
REST OF EUROPE: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET, BY MODALITY, 2022–2030 (USD MILLION)
TABLE 203
REST OF EUROPE: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET, BY BIOLOGICS, 2022–2030 (USD MILLION)
TABLE 204
REST OF EUROPE: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET, BY END USER, 2022–2030 (USD MILLION)
TABLE 205
MACROECONOMIC INDICATORS FOR ASIA PACIFIC
TABLE 206
ASIA PACIFIC: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET, BY COUNTRY, 2022–2030 (USD MILLION)
TABLE 207
ASIA PACIFIC: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET, BY PHASE, 2022–2030 (USD MILLION)
TABLE 208
ASIA PACIFIC: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET, BY SERVICE TYPE, 2022–2030 (USD MILLION)
TABLE 209
ASIA PACIFIC: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET, BY THERAPEUTIC AREA, 2022–2030 (USD MILLION)
TABLE 210
ASIA PACIFIC: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET, BY MODALITY, 2022–2030 (USD MILLION)
TABLE 211
ASIA PACIFIC: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET, BY BIOLOGICS, 2022–2030 (USD MILLION)
TABLE 212
ASIA PACIFIC CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET, BY END USER, 2022–2030 (USD MILLION)
TABLE 213
JAPAN: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET, BY PHASE, 2022–2030 (USD MILLION)
TABLE 214
JAPAN: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET, BY SERVICE TYPE, 2022–2030 (USD MILLION)
TABLE 215
JAPAN: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET, BY THERAPEUTIC AREA, 2022–2030 (USD MILLION)
TABLE 216
JAPAN: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET, BY MODALITY, 2022–2030 (USD MILLION)
TABLE 217
JAPAN: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET, BY BIOLOGICS, 2022–2030 (USD MILLION)
TABLE 218
JAPAN: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET, BY END USER, 2022–2030 (USD MILLION)
TABLE 219
CHINA: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET, BY PHASE, 2022–2030 (USD MILLION)
TABLE 220
CHINA: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET, BY SERVICE TYPE, 2022–2030 (USD MILLION)
TABLE 221
CHINA: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET, BY THERAPEUTIC AREA, 2022–2030 (USD MILLION)
TABLE 222
CHINA: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET, BY MODALITY, 2022–2030 (USD MILLION)
TABLE 223
CHINA: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET, BY BIOLOGICS, 2022–2030 (USD MILLION)
TABLE 224
CHINA: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET, BY END USER, 2022–2030 (USD MILLION)
TABLE 225
INDIA: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET, BY PHASE, 2022–2030 (USD MILLION)
TABLE 226
INDIA: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET, BY SERVICE TYPE, 2022–2030 (USD MILLION)
TABLE 227
INDIA: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET, BY THERAPEUTIC AREA, 2022–2030 (USD MILLION)
TABLE 228
INDIA: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET, BY MODALITY, 2022–2030 (USD MILLION)
TABLE 229
INDIA: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET, BY BIOLOGICS, 2022–2030 (USD MILLION)
TABLE 230
INDIA: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET, BY END USER, 2022–2030 (USD MILLION)
TABLE 231
REST OF ASIA PACIFIC: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET, BY PHASE, 2022–2030 (USD MILLION)
TABLE 232
REST OF ASIA PACIFIC: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET, BY SERVICE TYPE, 2022–2030 (USD MILLION)
TABLE 233
REST OF ASIA PACIFIC: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET, BY THERAPEUTIC AREA, 2022–2030 (USD MILLION)
TABLE 234
REST OF ASIA PACIFIC: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET, BY MODALITY, 2022–2030 (USD MILLION)
TABLE 235
REST OF ASIA PACIFIC: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET, BY BIOLOGICS, 2022–2030 (USD MILLION)
TABLE 236
REST OF ASIA PACIFIC: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET, BY END USER, 2022–2030 (USD MILLION)
TABLE 237
MACROECONOMIC INDICATORS FOR LATIN AMERICA
TABLE 238
LATIN AMERICA: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET, BY PHASE, 2022–2030 (USD MILLION)
TABLE 239
LATIN AMERICA: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET, BY SERVICE TYPE, 2022–2030 (USD MILLION)
TABLE 240
LATIN AMERICA: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET, BY THERAPEUTIC AREA, 2022–2030 (USD MILLION)
TABLE 241
LATIN AMERICA: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET, BY MODALITY, 2022–2030 (USD MILLION)
TABLE 242
LATIN AMERICA: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET, BY BIOLOGICS, 2022–2030 (USD MILLION)
TABLE 243
LATIN AMERICA: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET, BY END USER, 2022–2030 (USD MILLION)
TABLE 244
MACROECONOMIC INDICATORS FOR MIDDLE EAST & AFRICA
TABLE 245
MIDDLE EAST & AFRICA: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET, BY PHASE, 2022–2030 (USD MILLION)
TABLE 246
MIDDLE EAST & AFRICA: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET, BY SERVICE TYPE, 2022–2030 (USD MILLION)
TABLE 247
MIDDLE EAST & AFRICA: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET, BY THERAPEUTIC AREA, 2022–2030 (USD MILLION)
TABLE 248
MIDDLE EAST & AFRICA: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET, BY MODALITY, 2022–2030 (USD MILLION)
TABLE 249
MIDDLE EAST & AFRICA: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET, BY BIOLOGICS, 2022–2030 (USD MILLION)
TABLE 250
MIDDLE EAST & AFRICA: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET, BY END USER, 2022–2030 (USD MILLION)
TABLE 251
OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS IN CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET, 2022–2025
TABLE 252
CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET: DEGREE OF COMPETITION
TABLE 253
CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET: REGION FOOTPRINT
TABLE 254
CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET: PRODUCT TYPE FOOTPRINT
TABLE 255
CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET: THERAPEUTIC AREA FOOTPRINT
TABLE 256
CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET: PHASE FOOTPRINT
TABLE 257
CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET: DETAILED LIST OF KEY STARTUPS/SMES
TABLE 258
CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET: COMPETITIVE BENCHMARKING OF KEY STARTUPS/SMES
TABLE 259
CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET: PRODUCT LAUNCHES, JANUARY 2022–JANUARY 2025
TABLE 260
CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET: DEALS, JANUARY 2022–JANUARY 2025
TABLE 261
CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET: EXPANSIONS, JANUARY 2022–JANUARY 2025
TABLE 262
CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET: OTHER DEVELOPMENTS, JANUARY 2022–JANUARY 2025
TABLE 263
THERMO FISHER SCIENTIFIC INC.: COMPANY OVERVIEW
TABLE 264
THERMO FISHER SCIENTIFIC INC.: PRODUCTS/SERVICES OFFERED
TABLE 265
THERMO FISHER SCIENTIFIC INC: PRODUCT LAUNCHES, JANUARY 2022– JANUARY 2025
TABLE 266
THERMO FISHER SCIENTIFIC INC.: DEALS, JANUARY 2022–JANUARY 2025
TABLE 267
THERMO FISHER SCIENTIFIC INC.: EXPANSIONS, JANUARY 2022–JANUARY 2025
TABLE 268
IQVIA: COMPANY OVERVIEW
TABLE 269
IQVIA: PRODUCTS/SERVICES OFFERED
TABLE 270
IQVIA: PRODUCT LAUNCHES, JANUARY 2022–JANUARY 2025
TABLE 271
IQVIA: DEALS, JANUARY 2022–JANUARY 2025
TABLE 272
ICON PLC: COMPANY OVERVIEW
TABLE 273
ICON PLC: PRODUCTS/SERVICES OFFERED
TABLE 274
ICON PLC: PRODUCT LAUNCHES, JANUARY 2022–JANUARY 2025
TABLE 275
ICON PLC: DEALS, JANUARY 2022–JANUARY 2025
TABLE 276
CHARLES RIVER LABORATORIES: COMPANY OVERVIEW
TABLE 277
CHARLES RIVER LABORATORIES: PRODUCTS/SERVICES OFFERED
TABLE 278
CHARLES RIVER LABORATORIES: DEALS, JANUARY 2022–JANUARY 2025
TABLE 279
CHARLES RIVER LABORATORIES: EXPANSIONS, JANUARY 2022–JANUARY 2025
TABLE 280
LABCORP: COMPANY OVERVIEW
TABLE 281
LABCORP: PRODUCTS/SERVICES OFFERED
TABLE 282
LABCORP: PRODUCTS LAUNCHES, JANUARY 2022–JANUARY 2025
TABLE 283
LABCORP: DEALS, JANUARY 2022–JANUARY 2025
TABLE 284
LABCORP: EXPANSIONS, JANUARY 2022–JANUARY 2025
TABLE 285
LABCORP: OTHER DEVELOPMENTS, JANUARY 2022–JANUARY 2025
TABLE 286
QUEST DIAGNOSTICS: COMPANY OVERVIEW
TABLE 287
QUEST DIAGNOSTICS: PRODUCTS/SERVICES OFFERED
TABLE 288
QUEST DIAGNOSTICS: DEALS, JANUARY 2022–JANUARY 2025
TABLE 289
MEDPACE: COMPANY OVERVIEW
TABLE 290
MEDPACE: PRODUCTS/SERVICES OFFERED
TABLE 291
MEDPACE: EXPANSIONS, JANUARY 2022–JANUARY 2025
TABLE 292
FRONTAGE LABS: COMPANY OVERVIEW
TABLE 293
FRONTAGE LABS: PRODUCTS/SERVICES OFFERED
TABLE 294
SGS SOCIÉTÉ GÉNÉRALE DE SURVEILLANCE SA: COMPANY OVERVIEW
TABLE 295
SGS SOCIÉTÉ GÉNÉRALE DE SURVEILLANCE SA: PRODUCTS/SERVICES OFFERED
TABLE 296
SGS SOCIÉTÉ GÉNÉRALE DE SURVEILLANCE SA: DEALS, JANUARY 2022– JANUARY 2025
TABLE 297
EUROFINS SCIENTIFIC: COMPANY OVERVIEW
TABLE 298
EUROFINS SCIENTIFIC: PRODUCTS/SERVICES OFFERED
TABLE 299
EUROFINS SCIENTIFIC: DEALS, JANUARY 2022–JANUARY 2025
TABLE 300
REPROCELL INC.: COMPANY OVERVIEW
TABLE 301
REPROCELL INC.: PRODUCTS/SERVICES OFFERED
TABLE 302
REPROCELL INC.: DEALS, JANUARY 2022–JANUARY 2025
TABLE 303
ACM GLOBAL LABORATORIES: COMPANY OVERVIEW
TABLE 304
ACM GLOBAL LABORATORIES: PRODUCTS/SERVICES OFFERED
TABLE 305
ACM GLOBAL LABORATORIES: DEALS, JANUARY 2022–JANUARY 2025
TABLE 306
WORLDWIDE CLINICAL TRIALS: COMPANY OVERVIEW
TABLE 307
VERSITI: COMPANY OVERVIEW
TABLE 308
CTI CLINICAL TRIAL & CONSULTING: COMPANY OVERVIEW
TABLE 309
CLARITY LABORATORIES, INC: COMPANY OVERVIEW
TABLE 310
NOVOTECH: COMPANY OVERVIEW
TABLE 311
ARUP LABORATORIES: COMPANY OVERVIEW
TABLE 312
PRECISION MEDICINE GROUP: COMPANY OVERVIEW
TABLE 313
BIOAGILYTIX LABS: COMPANY OVERVIEW
TABLE 314
CERBA HEALTHCARE: COMPANY OVERVIEW
TABLE 315
ALMAC GROUP: COMPANY OVERVIEW
TABLE 316
MLM MEDICAL LABS: COMPANY OVERVIEW
TABLE 317
SALVUS BIORESEARCH SOLUTIONS LLP: COMPANY OVERVIEW
TABLE 318
UNILABS: COMPANY OVERVIEW
LIST OF FIGURES
FIGURE 1
CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET SEGMENTATION AND REGIONAL SCOPE
FIGURE 2
CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET: RESEARCH DESIGN
FIGURE 3
BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION
FIGURE 4
COMPANY REVENUE ESTIMATION APPROACH: BOTTOM-UP APPROACH
FIGURE 5
CAGR PROJECTIONS: SUPPLY-SIDE ANALYSIS
FIGURE 6
CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET: TOP-DOWN APPROACH
FIGURE 7
DATA TRIANGULATION METHODOLOGY
FIGURE 8
CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET, BY PHASE, 2025 VS. 2030 (USD MILLION)
FIGURE 9
CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET, BY SERVICE TYPE, 2025 VS. 2030 (USD MILLION)
FIGURE 10
CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET, BY THERAPEUTIC AREA, 2025 VS. 2030 (USD MILLION)
FIGURE 11
CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET, BY MODALITY, 2025 VS. 2030 (USD MILLION)
FIGURE 12
CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET, BY END USER, 2025 VS. 2030 (USD MILLION)
FIGURE 13
GEOGRAPHICAL SNAPSHOT OF CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET
FIGURE 14
INCREASING PREVALENCE OF RARE DISEASES TO DRIVE MARKET
FIGURE 15
PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES SEGMENT AND CHINA LED ASIA PACIFIC MARKET IN 2024
FIGURE 16
CHINA TO RECORD HIGHEST GROWTH RATE FROM 2025 TO 2030
FIGURE 17
ASIA PACIFIC TO WITNESS HIGHEST GROWTH DURING FORECAST PERIOD
FIGURE 18
CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
FIGURE 19
TRENDS/DISRUPTIONS IMPACTING CUSTOMER BUSINESS
FIGURE 20
CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET: VALUE CHAIN ANALYSIS
FIGURE 21
CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET: ECOSYSTEM ANALYSIS
FIGURE 22
CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET: INVESTMENT AND FUNDING SCENARIO, 2022−2025
FIGURE 23
CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET: PORTER’S FIVE FORCES ANALYSIS
FIGURE 24
INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS, BY END USER
FIGURE 25
KEY BUYING CRITERIA, BY END USER
FIGURE 26
AI USE CASES
FIGURE 27
NORTH AMERICA: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET SNAPSHOT
FIGURE 28
ASIA PACIFIC: CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET SNAPSHOT
FIGURE 29
REVENUE ANALYSIS OF KEY PLAYERS, 2020−2024 (USD MILLION)
FIGURE 30
MARKET SHARE ANALYSIS OF KEY PLAYERS, 2024
FIGURE 31
RANKING OF KEY PLAYERS IN CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET, 2024
FIGURE 32
YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK BETA OF KEY VENDORS, 2025
FIGURE 33
FINANCIAL METRICS, 2025
FIGURE 34
CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET: BRAND/PRODUCT COMPARISON
FIGURE 35
CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET: COMPANY EVALUATION MATRIX (KEY PLAYERS), 2024
FIGURE 36
CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET: COMPANY FOOTPRINT
FIGURE 37
CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET: COMPANY EVALUATION MATRIX (STARTUPS/SMES), 2024
FIGURE 38
THERMO FISHER SCIENTIFIC INC.: COMPANY SNAPSHOT (2024)
FIGURE 39
IQVIA: COMPANY SNAPSHOT (2024)
FIGURE 40
ICON PLC: COMPANY SNAPSHOT (2023)
FIGURE 41
CHARLES RIVER LABORATORIES: COMPANY SNAPSHOT (2023)
FIGURE 42
LABCORP: COMPANY SNAPSHOT (2024)
FIGURE 43
QUEST DIAGNOSTICS: COMPANY SNAPSHOT (2024)
FIGURE 44
MEDPACE: COMPANY SNAPSHOT (2024)
FIGURE 45
FRONTAGE LABS: COMPANY SNAPSHOT (2023)
FIGURE 46
SGS SOCIÉTÉ GÉNÉRALE DE SURVEILLANCE SA: COMPANY SNAPSHOT (2024)
FIGURE 47
EUROFINS SCIENTIFIC: COMPANY SNAPSHOT (2024)
Methodology
This research study involved the extensive use of secondary sources, directories, and databases to identify and collect valuable information for the analysis of the global clinical trial services market. In-depth interviews were conducted with various primary respondents, including key industry participants, subject-matter experts (SMEs), C-level executives of key market players, and industry consultants, to obtain and verify critical qualitative and quantitative information and assess the growth prospects of the market. The global market size estimated through secondary research was then triangulated with inputs from primary research to arrive at the final market size.
Secondary Research
The market for the companies offering clinical trial services is arrived at by secondary data available through paid and unpaid sources, analyzing the service portfolios of the major companies in the ecosystem, and rating the companies by their performance and quality. Various sources were referred to in the secondary research process to identify and collect information for this study. The secondary sources include annual reports, press releases, investor presentations of companies, white papers, journals, certified publications, and articles from recognized authors, directories, and databases. The secondary research was used to obtain critical information on the industry’s value chain, the total pool of key players, market classification, and segmentation from the market and technology-oriented perspectives. Secondary data was analyzed to arrive at the overall size of the global clinical trial services market, which was validated through primary research.
Primary Research
Extensive primary research was conducted after acquiring basic knowledge about the global clinical trial services market scenario through secondary research. Several primary interviews were conducted with market experts from the demand side, such as pharmaceutical and medical device companies, and experts from the supply side, such as C-level and D-level executives, and trial managers. These interviews were conducted across major regions, namely, North America, Europe, the Asia Pacific, and the Rest of the World (including Latin America, the Middle East, and Africa). This primary data was collected through questionnaires, e-mails, online surveys, personal interviews, and telephonic interviews.
In the complete market engineering process, the top-down and bottom-up approaches were extensively used, along with several data triangulation methods, to perform the market estimation and market forecasting for the overall market segments and subsegments listed in this report. Extensive qualitative and quantitative analysis was performed on the complete market engineering process to list the key information/insights throughout the report.
The following is a breakdown of the primary respondents:
To know about the assumptions considered for the study, download the pdf brochure
Market Size Estimation
The global size of the clinical trial services market was estimated and validated through multiple approaches such as the top-down and bottom-up approaches. These methods were also used extensively to estimate the size of various subsegments in the markets.
The research methodology used to estimate the market size includes the following:
The key players in the clinical trial services market were been identified through extensive primary and secondary research.
The revenues generated from the clinical trial services businesses of leading players were determined through primary and secondary research.
All percentage shares, splits, and breakdowns for respective market segments were determined using secondary sources and verified through primary sources.
Data Triangulation
After arriving at the market size from the market size estimation process explained above, the total market was divided into several segments and subsegments. To complete the overall market engineering process and arrive at the exact statistics for all segments and subsegments, data triangulation and market breakdown procedures were employed, wherever applicable.
Market Definition
Clinical trials are research studies that evaluate the safety, efficacy, and therapeutic benefits of new drugs, biologics, and medical devices in humans. The clinical trial services market refers to contracting third-party service providers, such as Contract Research Organizations (CROs), by pharmaceutical, biotechnology, and medical device companies to manage and conduct clinical trials between phase I to phase IV. This market includes various services such as patient recruitment, site management, data monitoring, regulatory compliance, and statistical analysis, among others supporting the development of various drug modalities such as small molecules, biologics, and medical devices across therapeutic areas like oncology, neurology, and respiratory disorders, among others. The market also includes different service delivery models to meet the sponsor’s needs, such as Full-Service Outsourcing (FSO), Functional Service Provision (FSP), and hybrid models.
Stakeholders
- Contract Research Organizations (CROs)/Clinical Trial Service Providers
- Pharmaceutical and Biopharmaceutical Companies
- Medical Device Manufacturing Companies
- Academic and Research Institutes
- Venture Capitalists and Investors
- Market Research and Consulting Firms
- Government Associations
- Medical Institutions and Universities
Report Objectives
- To define, describe, and forecast the clinical trial services market based on phase, service type, therapy area, modality, delivery model, study design, end users/sponsor, and region
- To provide detailed information regarding the major factors influencing the market growth, such as drivers, restraints, opportunities, and challenges
- To strategically analyze the micromarkets with respect to individual growth trends, future prospects, and contributions to the overall precision medicine market
- To analyze the opportunities in the market for stakeholders and provide details of the competitive landscape for market leaders
- To analyze subsegments of the market with respect to individual growth trends, prospects, and contributions to the overall market
- To forecast the revenue of the market segments with respect to six main regions, namely, North America (US and Canada), Europe (Germany, UK, France, Italy, Spain, and the Rest of Europe), Asia Pacific (China, Japan, India, Australia, South Korea and the Rest of Asia Pacific), Latin America (Brazil, Mexico, and Rest of Latin America, the Middle East (GCC and Rest of Middle East) and Africa.
- To profile the key market players and comprehensively analyze their market shares and core competencies2
- To track and analyze competitive developments such as service launches, agreements, partnerships, acquisitions, business expansions, and research & development activities in the clinical trial services market.
Need a Tailored Report?
Customize this report to your needs
Get 10% FREE Customization
Customize This Report
Fact checked
Personalize This Research
- Triangulate with your Own Data
- Get Data as per your Format and Definition
- Gain a Deeper Dive on a Specific Application, Geography, Customer or Competitor
- Any level of Personalization
Let Us Help You
- What are the Known and Unknown Adjacencies Impacting the Clinical Trial Services Market
- What will your New Revenue Sources be?
- Who will be your Top Customer; what will make them switch?
- Defend your Market Share or Win Competitors
- Get a Scorecard for Target Partners
Custom Market Research Services
We Will Customise The Research For You, In Case The Report Listed Above Does Not Meet With Your Requirements
Get 10% Free CustomisationGrowth opportunities and latent adjacency in Clinical Trial Services Market
Olivia
Mar, 2022
Which segment, Based on the therapy area, accounted for the major share of the global Clinical Trials Market?.
Adam
Mar, 2022
Can you share the detailed report on the geographical analysis of the global Clinical Trials Market?.
Henry
Mar, 2022
Which of the global leaders holds the largest share of the global Clinical Trials Market?.